Crizotinib
- Generic Name
- Crizotinib
- Brand Names
- Xalkori
- Drug Type
- Small Molecule
- Chemical Formula
- C21H22Cl2FN5O
- CAS Number
- 877399-52-5
- Unique Ingredient Identifier
- 53AH36668S
- Background
Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusio...
- Indication
Crizotinib is a kinase inhibitor indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as detected by an FDA-approved test. Crizotinib is also indicated for the treatment of relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK...
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer, Refractory Anaplastic Large Cell Lymphoma, Recurrent Inflammatory Myofibroblastic Tumors, Refractory Inflammatory Myofibroblastic Tumors, Relapsed Anaplastic Large Cell Lymphoma, Unresectable Inflammatory Myofibroblastic Tumors
- Associated Therapies
- -
Crizotinib Continuation Clinical Study
- First Posted Date
- 2021-12-16
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 26
- Registration Number
- NCT05160922
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Science, Beijing, Beijing, China
🇨🇳The First Affiliated Hospital of Guangzhou Medical University., Guangzhou, China
🇨🇳West China Hospital of Sichuan University, Wuhou District,Chengdu, Sichuan, China
ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma
- First Posted Date
- 2021-08-20
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Hunan Province Tumor Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT05014464
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
Bioequivalence Study for Crizotinib Encapsulated Microsphere Formulation (eMS)
- First Posted Date
- 2021-04-23
- Last Posted Date
- 2022-01-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 25
- Registration Number
- NCT04856293
- Locations
- 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
- First Posted Date
- 2021-01-05
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 111
- Registration Number
- NCT04693468
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.
- Conditions
- Interventions
- First Posted Date
- 2020-11-30
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 549
- Registration Number
- NCT04647110
- Locations
- 🇸🇪
Pfizer Innovations AB, Sollentuna, Sweden
Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
- Conditions
- Interventions
- First Posted Date
- 2020-11-17
- Last Posted Date
- 2023-11-24
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 292
- Registration Number
- NCT04632758
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
- Conditions
- Interventions
- First Posted Date
- 2020-10-27
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 220
- Registration Number
- NCT04603807
- Locations
- 🇩🇪
HELIOS Klinikum Emil von Behring Klinik f.Pneumologie Onkologie u.Infektiologie, Berlin, Germany
🇩🇪Kliniken Maria Hilf; Klinik für Hämatologie, Onkologie und Gastroenterologie, Mönchengladbach, Germany
🇮🇳Mahamana Pandit Madan Mohan Malaviya Cancer Centre-TMC, Varanasi, Uttar Pradesh, India
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)
- Conditions
- Interventions
- First Posted Date
- 2020-06-19
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 5
- Registration Number
- NCT04439266
- Locations
- 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)
- Conditions
- Interventions
- First Posted Date
- 2020-06-19
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 4
- Registration Number
- NCT04439253
- Locations
- 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States
Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC
- First Posted Date
- 2020-03-26
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Hunan Province Tumor Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT04322578
- Locations
- 🇨🇳
Yongchang Zhang, Changsha, Hunan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.